Taselisib
Tier C — Watch / tradeTaselisib
Targets：PI3Kβ, PI3Kα, PI3Kγ, PI3Kδ
Indications (approved)：Breast cancer, Bladder cancer, Multiple myeloma, Lung cancer, Liver cancer, Cervical cancer, Melanoma, Thyroid cancer
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| TASE-001 | 22532-62-3 | 4-bromo-2-hydroxybenzaldehyde |
| TASE-002 | 1282516-66-8 | 5-bromo-2-(1H-imidazol-2-yl)phenol |
| TASE-003 | 106-93-4Available | 1,2-dibromoethane |
| TASE-004 | 1282516-67-9 | 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| TASE-005 | 1282516-68-0 | 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| TASE-006 | 1282516-69-1 | 9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| TASE-007 | 999-97-3 | bis(trimethylsilyl)amine |
| TASE-008 | 1282516-65-7 | 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide |
| TASE-009 | 18871-66-4 | 1,1-dimethoxy-N,N-dimethylethanamine |
| TASE-010 | 1282514-63-9 | 9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| TASE-011 | 1282518-81-3 | 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| TASE-010 | 1282514-63-9 | 9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| TASE-012 | 105942-08-3 | 4-bromo-2-fluorobenzonitrile |
| TASE-013 | 635702-31-7 | 4-bromo-2-fluoro-N-hydroxybenzimidamide |
| TASE-014 | 623-47-2Available | ethyl propiolate |
| TASE-015 | 1628256-44-9 | ethyl 3-((4-bromo-2-fluorobenzimidamido)oxy)acrylate |
| TASE-016 | 1628256-45-0 | ethyl 2-(4-bromo-2-fluorophenyl)-1H-imidazole-4-carboxylate |
| TASE-017 | 96-49-1 | 1,3-dioxolan-2-one |
| TASE-018 | 1628256-46-1 | ethyl 2-(4-bromo-2-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazole-4-carboxylate |
| TASE-019 | 1282516-74-8 | 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylic acid |
| TASE-020 | 1628256-47-2 | 9-bromo-N-(1-iminoethyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide |
| TASE-021 | 1201657-32-0 | ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate |
| TASE-022 | 1282514-64-0 | ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate |
| TASE-023 | 1282513-03-4 | 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid |
| TASE-024 | 600-00-0 | ethyl 2-bromo-2-methylpropanoate |
| TASE-025 | 288-13-1Available | 1H-pyrazole |
| TASE-026 | 1461761-37-4 | ethyl 2-methyl-2-(1H-pyrazol-1-yl)propanoate |
| TASE-027 | 23078-57-1 | 2,5-dibromo-4,4-dimethylcyclopentane-1,3-dione |
| TASE-028 | 1040377-17-0 | ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate |
| TASE-029 | 73183-34-3Available | 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) |
Frequently asked questions
What are the approved indications of Taselisib?
Approved indications include: Breast cancer, Bladder cancer, Multiple myeloma, Lung cancer, Liver cancer, Cervical cancer, Melanoma, Thyroid cancer.
When does the Taselisib patent expire?
No public expiry year is available for Taselisib yet; this page updates once verified.
How many synthesis routes are recorded for Taselisib?
2 synthesis routes are recorded; the shortest is 8 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Taselisib intermediates?
4 intermediate CAS of Taselisib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Taselisib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11